Department of Pharmacology and Physiology, College of Medicine, Drexel University, Philadelphia, PA 19102, United States.
Department of Neurology, Drexel Neuroscience Institute, Philadelphia, PA 19107, United States.
Prog Neuropsychopharmacol Biol Psychiatry. 2018 Jul 13;85:136-151. doi: 10.1016/j.pnpbp.2017.08.004. Epub 2017 Aug 10.
Chronic stress is a risk factor for a number of physiological disorders including cardiovascular disease, obesity and gastrointestinal disorders, as well as psychiatric and neurodegenerative disorders. There are a number of underlying molecular and cellular mechanisms altered in the course of chronic stress, which may increase the vulnerability of individuals to develop psychiatric disorders such as depression, and neurodegenerative disorders such as Alzheimer's Disease (AD). This is evident in the influence of stress on large-scale brain networks, including the resting state Default Mode Network (DMN), the effects of stress on neuronal circuitry and architecture, and the cellular and molecular adaptations to stress, which may render individuals with stress related psychiatric disorders more vulnerable to neurodegenerative disease later in life. These alterations include decreased negative feedback inhibition of the hypothalamic pituitary axis (HPA) axis, decreased dendritic arborization and spine density in the prefrontal cortex (PFC) and hippocampus, and the release of proinflammatory cytokines, which may suppress neurogenesis and promote neuronal cell death. Each of these factors are thought to play a role in stress-related psychiatric disease as well as AD, and have been observed in clinical and post-mortem studies of individuals with depression and AD. The goal of the current review is to summarize clinical and preclinical evidence supporting a role for chronic stress as a putative link between neuropsychiatric and neurodegenerative disease. Moreover, we provide a rationale for the importance of taking a medical history of stress-related psychiatric diseases into consideration during clinical trial design, as they may play an important role in the etiology of AD in stratified patient populations.
慢性应激是许多生理紊乱的一个风险因素,包括心血管疾病、肥胖和胃肠道紊乱,以及精神疾病和神经退行性紊乱。在慢性应激过程中,有许多潜在的分子和细胞机制发生改变,这可能会增加个体易患精神疾病(如抑郁症)和神经退行性疾病(如阿尔茨海默病)的脆弱性。这在应激对大脑大网络的影响中显而易见,包括静息状态默认模式网络(DMN)、应激对神经元回路和结构的影响,以及对应激的细胞和分子适应,这可能使有应激相关精神疾病的个体在以后的生活中更容易患神经退行性疾病。这些改变包括下丘脑-垂体轴(HPA)轴负反馈抑制的减少、前额叶皮层(PFC)和海马体树突分支和棘密度的减少,以及促炎细胞因子的释放,这些可能会抑制神经发生并促进神经元细胞死亡。这些因素都被认为在应激相关的精神疾病和 AD 中起作用,并且在抑郁和 AD 个体的临床和死后研究中已经观察到。目前综述的目的是总结支持慢性应激作为神经精神和神经退行性疾病之间潜在联系的临床和临床前证据。此外,我们还为在临床试验设计中考虑应激相关精神疾病的病史提供了一个理由,因为它们在分层患者人群中 AD 的病因学中可能起着重要作用。